Everything below concerns storage stability. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-24. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
== Target == Phrixotoxin-1 and -2 bind to A-type, transient, voltage-gated potassium channels, near the S3 and S4 segments, where they negatively affect transmembrane movement of the voltage sensing domain in response to depolarizing voltages. They bind preferentially to the closed or inactivated state of Kv4.2 and Kv4.3 channels(Chagot 2004). Phrixotoxin-3 (PaurTx3) inhibits several voltage gated sodium channel subtypes (Nav1.1/SCN1A, Nav1.2/SCN2A, Nav1.4/SCN4A, Nav1.5/SCN5A, and Nav1.8/SCN10A) (Bosmans 2006).
Due to the legal and military tensions, the Hungarian parliament did not grant Franz Joseph that favour. Francis Joseph was, in the strict constitutional sense, a textbook usurper in Hungary: under the Pragmatic Sanction of 1723 (Arts. I–III) and the established Hungarian constitutional law governing succession and coronation, the throne was not vacant while the crowned King Ferdinand V was still alive, and Ferdinand’s unilateral abdication could not by itself make Francis Joseph King of Hungary; without the consent of the Hungarian Diet, the constitutional oath, and coronation with the Holy Crown, Francis Joseph had no lawful authority to exercise the Hungarian royal power—his seizure of that power thus constituting a clear case of usurpation. In short: Francis Joseph was regarded by Hungarians as a usurper and a rebel against the ancient constitution and the established order.
No human pathogens of comparable virulence have yet emerged from marine species. In 2024 aquaculture production was concentrated in Asia which accounted for around 89% of global aquatic animal aquaculture production, followed by Latin America and the Caribbean (3%), Europe (2%), Africa (2%), Northern America (0.4%) and Oceania (0.2%). The top five countries together produced 82% of the total output; China, Indonesia, India, Viet Nam and Bangladesh. Freshwater systems dominate aquaculture production of aquatic animals, accounting for 64 million tonnes (63%), compared to 38 million tonnes (37%) from marine and coastal systems. Biological control methods to manage parasites are already being used, such as cleaner fish (e.g. lumpsuckers and wrasse) to control sea lice populations in salmon farming. Models are being used to help with spatial planning and siting of fish farms in order to minimize impact.
The two substrates of this enzyme are shikimate and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are 3-dehydroshikimate, reduced NADPH, and a proton. This enzyme participates in phenylalanine, tyrosine and tryptophan biosynthesis.
Sources: en.wikipedia.org
The Committee on International Affairs of the State Duma (Russian: Комитет Государственной Думы по международным делам) is a committee of the State Duma, the lower house of Russia's Federal Assembly. The Committee carries out activities in the field of implementation of Russia's foreign policy, international contacts of the State Duma, work in interparliamentary structures, and relations with parliaments of other states. The Committee checks the international treaties subject to ratification and gives its conclusion, after which the draft treaties are put to the vote of the State Duma. Also, the Committee considers candidates proposed by the Russian President for the posts of ambassadors to foreign countries and international organizations and makes its recommendations regarding their appointment to the proposed positions.
The initial use of racemic dopa for the treatment of Parkinson's disease resulted in a number of adverse effects viz. nausea, vomiting, anorexia, involuntary movements and granulocytopenia. The use of L-dopa [the (S)-enantiomer] resulted in reducing the required dose, and adverse effects. The granulocytopenia was not observed with the single enantiomer.
Underworld is a 2003 action horror film directed by Len Wiseman in his feature film directorial debut, from a screenplay by Danny McBride, based on a story by Kevin Grevioux, Wiseman, and McBride. The film stars Kate Beckinsale, Scott Speedman, Michael Sheen, Shane Brolly, Erwin Leder, and Bill Nighy. The plot centers on the secret history of vampires and lycans (an abbreviated form of lycanthrope, which means werewolf). The main plot revolves around Selene (Beckinsale), a vampire Death Dealer hunting Lycans. She finds herself attracted to a human, Michael Corvin (Speedman), who is being targeted by the Lycans. After Michael is bitten by a Lycan, Selene must decide whether to do her duty and kill him or go against her clan and save him. Underworld premiered at the Grauman's Chinese Theatre in Los Angeles, California on September 15, 2003, and was released in the United States on September 19, by Sony Pictures Releasing under the Screen Gems banner. The film received generally mixed-to-negative reviews from critics. A surprise hit, the film grossed over $95 million worldwide against a production budget of $22 million and originated a franchise. The film was followed by Underworld: Evolution in 2006.
Induces endometrial secretory transformation in preparation for pregnancy (>5 ng/mL) Prevents estrogen-induced endometrial hyperplasia and increased endometrial cancer risk Maintains pregnancy via effects in endometrium (with withdrawal resulting in miscarriage) Reduces amount and fibrosity of cervical mucus and causes cervix to become firmer and more tightly closed Controls motility and composition of fluid in the fallopian tubes Reduced cornification and maturation of the vaginal lining Causes water retention in the breasts resulting in temporary enlargement during the menstrual cycle Mediates lobuloalveolar development of the breasts necessary for lactation Suppresses lactation initiation and triggers lactation upon withdrawal (as with parturition) Maintains skin health, integrity, appearance, and hydration and slows the rate of aging of the skin Modulates brain function, with effects on mood, emotionality, and sexuality, as well as cognition and memory Exerts negative feedback on the hypothalamic–pituitary–gonadal axis (HPG axis) by suppressing the secretion of the gonadotropins FSH and LH from the pituitary gland (including the mid-cycle gonadotropin surge), thereby inhibiting gonadal sex hormone production as well as ovulation and fertility (>2 ng/mL) Increases basal body temperature (by 0.3–0.6 °C (0.5–1.0 °F) relative to preovulation) via the hypothalamus (>4 ng/mL) Reduces hot flashes via the hypothalamus Stimulates respiration via the hypothalamus and/or respiratory center Influences the risk and/or progression of hormone-sensitive cancers including breast cancer and endometrial cancer Many of the effects of progesterone require estrogen, as estrogens prime tissues for progesterone by inducing expression of the PRs. The PRs are induced in the breasts by estrogens, and for this reason, it is assumed that progestogens cannot mediate breast changes in the absence of estrogens. Progesterone also lowers blood pressure and reduces water and salt retention among other effects via its antimineralocorticoid activity. Progesterone can produce sedative, hypnotic, anxiolytic, euphoric, cognitive-, memory-, and motor-impairing, anticonvulsant, and even anesthetic effects via formation of sufficiently high concentrations of its neurosteroid metabolites and consequent GABAA receptor potentiation in the brain.
Jens Juul Holst (born 31 August 1945) is a Danish physician and physiologist. He is known for discovering and describing the hormone glucagon-like peptide-1 (GLP-1), a hormone in the gut that plays an important role in the onset and development of Type 2 diabetes. In collaboration with researcher and author Arne Astrup, he discovered that GLP-1 acts as a satiety hormone in humans. In 2020, he was awarded the Warren Alpert Foundation Prize along Daniel J. Drucker and Joel F. Habener. In 2021, he was awarded the Canada Gairdner International Award along Daniel J. Drucker, Joel F. Habener, and Mary-Claire King. He was also awarded the Banting Medal by the American Diabetes Association (ADA). In 2024, he was awarded the Princess of Asturias Awards for Technical and Scientific Research along Daniel J. Drucker, Jeffrey M. Friedman, Joel F. Habener, and Svetlana Mojsov. In 2024, he received the Tang Prize in the category of "Biopharmaceutical Science", and the BBVA Foundation Frontiers of Knowledge Award in the category "Biology and Biomedicine". In 2025, he received the Breakthrough Prize in Life Sciences alongside Daniel Drucker, Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen).
Sources: en.wikipedia.org
=== Pore size === Many stationary phases are porous to provide greater surface area. Small pores provide greater surface area while larger pore size has better kinetics, especially for larger analytes. For example, a protein which is only slightly smaller than a pore might enter the pore but does not easily leave once inside.
== Research == AAS, alone and in combination with progestogens, have been studied as potential male hormonal contraceptives. Dual AAS and progestins such as trestolone and dimethandrolone undecanoate have also been studied as male contraceptives, with the latter under active investigation as of 2018. Topical androgens have been used and studied in the treatment of cellulite in women. Topical androstanolone on the abdomen has been found to significantly decrease subcutaneous abdominal fat in women, and hence may be useful for improving body silhouette. However, men and hyperandrogenic women have higher amounts of abdominal fat than healthy women, and androgens have been found to increase abdominal fat in postmenopausal women and transgender men as well.
Microarrays can also be used for detecting autoantibodies, utilizing autoantigen arrays to screen against many antigens or potential antigens in parallel. Treatment development involves the development of antigen-specific therapies for autoimmunity, cancer and allergies; the identification of small molecule targets that could potentially be used as new drugs.
== Analysis == A wide range of instrumental techniques are employed in nuclear forensics. Radiometric counting techniques are useful when determining decay products of species with short half-lives. However, for longer half-lives, inorganic mass spec is a powerful means of carrying out elemental analysis and determining isotopic relationships. Microscopy approaches can also be useful in characterization of a nuclear material.
Nicotinamide is recommended as a treatment for niacin deficiency because it can be administered in remedial amounts without causing the flushing, considered an adverse effect. In the past, the group was loosely referred to as vitamin B3 complex. Extra-terrestrial nicotinic acid and nicotinamide have been detected in carbonaceous chondrite meteorites and in sample-returns from the asteroids 162173 Ryugu and 101955 Bennu.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.